尼洛替尼被批准用于治疗对其他疗法产生耐药性的慢性粒细胞白血病患者

2007-11-08 14:22:25   作者：   文字大小：【大】【中】【小】

MONDAY, Oct. 29 (HealthDay News) -- Tasigna (nilotinib) has been approved by the U.S. Food and Drug Administration to treat chronic myeloid leukemia (CML) in people who are resistant or intolerant to other therapies, maker Novartis AG said Monday.
Related News
制药公司诺华周一宣布，Tasigna（尼洛替尼）已被美国食品药品监管局（FDA）批准用于治疗那些对其他疗法产生耐药性或不能耐受的慢性粒细胞白血病患者。

CML, among the most common forms of leukemia, affects about 4,500 people in the United States each year. Some have become resistant to or cannot tolerate a standard therapy for CML, Gleevec.
慢性粒细胞白血病是最常见的白血病之一。在美国，每年约有4500人罹患慢性粒细胞白血病。一些患者已经对慢性粒细胞白血病的标准疗法——格列卫产生产生耐药性或不能耐受。

Tasigna, taken twice daily, targets a protein that is produced only by cells that have an abnormal chromosome in people with Philadelphia chromosome-positive CML, Novartis said in a statement. The protein is a key cause of the over-production of the white blood cells that characterizes this form of CML.
诺华公司在一份声明中表示，Tasigna（尼洛替尼）每日服用两次，靶向一种含有异常染色体细胞产生的蛋白质。费城染色体阳性的慢性粒细胞白血病患者体内含有该异常染色体细胞。这种蛋白质是白细胞异常增生的主要原因，而白细胞异常增生是慢性粒细胞白血病的一种表现。

Reported side effects of the drug include rash, nausea, fatigue, headache, constipation, diarrhea, and vomiting. Users should avoid food two hours before and one hour after taking Tasigna, Novartis said.
已报告的药物副作用包括皮疹，恶心，疲乏，头痛，便秘，腹泻和呕吐。诺华公司称，患者应在服用Tasigna（尼洛替尼）的前两个小时和后一小时内避免进食。